Report cover image

Global & Oman Cancer Therapeutics Market to 2031

Publisher Business Market Insights
Published Jun 04, 2025
Length 100 Pages
SKU # BMKS20063483

Description

According to the study Cancer Incidence in Oman 2020, the crude cancer incidence rates were 68.3 per 100,000 men and 79.4 per 100,000 women in the country. As the number of cancer patients rises, there is an increasing demand for effective treatment options, driving growth in the cancer therapeutics market. Oman’s Ministry of Health (MOH) has been actively working to strengthen the healthcare system, particularly in oncology. Key institutions such as Sultan Qaboos University Hospital (SQUH) and the Royal Hospital provide essential cancer care services. Additionally, the Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), a government-supported facility, opened in July 2021 to offer high-quality, evidence-based, patient-focused cancer treatment. The center is committed to delivering advanced care while fostering ongoing clinical and scientific advancements in cancer therapies.

In July 2023, the Ministry of Health in Oman approved Zepzelca (lurbinectedin) for use in adult patients with metastatic small cell lung cancer (SCLC) who have shown disease progression after platinum-based chemotherapy. Immedica, the distributor, had previously signed a strategic partnership with PharmaMar in 2020 for the exclusive distribution and commercialization of lurbinectedin across multiple regions including the UK, Ireland, Nordic countries, parts of Eastern Europe, and the Middle East and North Africa.

Table of Contents

100 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Data Triangulation and Validation:
4. Oman Cancer Therapeutics Market Landscape
4.1 Overview
4.2 Ecosystem Analysis
4.2.1 List of Vendors in the Value Chain
5. Cancer Therapeutics Market Key Market Dynamics
5.1 Cancer Therapeutics Market – Key Market Dynamics
5.2 Market Drivers
5.3 Market Restraints
5.4 Market Opportunities
5.5 Future Trends
5.6 Impact of Drivers and Restraints
6. Oman Cancer Therapeutics Market – Analysis
6.1 Oman Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
6.2 Oman Cancer Therapeutics Market Revenue and Forecast Analysis
7. Oman Cancer Therapeutics Market Analysis – by Therapy Types
7.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
8. Oman Cancer Therapeutics Market Analysis – by Indications
8.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
9. Oman Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.1 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.2 Partnerships and Collaborations
11.2 Other Developments
12. Company Profiles
12.1 Bristol-Myers Squibb Co
12.1. 1 Key Facts
12.1. 2 Business Description
12.1. 3 Products and Services
12.1. 4 Financial Overview
12.1. 5 SWOT Analysis
12.1. 6 Key Developments
12.2 AbbVie Inc
12.2. 1 Key Facts
12.2. 2 Business Description
12.2. 3 Products and Services
12.2. 4 Financial Overview
12.2. 5 SWOT Analysis
12.2. 6 Key Developments
12.3 Johnson & Johnson
12.3. 1 Key Facts
12.3. 2 Business Description
12.3. 3 Products and Services
12.3. 4 Financial Overview
12.3. 5 SWOT Analysis
12.3. 6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
12.4. 1 Key Facts
12.4. 2 Business Description
12.4. 3 Products and Services
12.4. 4 Financial Overview
12.4. 5 SWOT Analysis
12.4. 6 Key Developments
12.5 Pfizer Inc
12.5. 1 Key Facts
12.5. 2 Business Description
12.5. 3 Products and Services
12.5. 4 Financial Overview
12.5. 5 SWOT Analysis
12.5. 6 Key Developments
12.6 AstraZeneca Plc
12.6. 1 Key Facts
12.6. 2 Business Description
12.6. 3 Products and Services
12.6. 4 Financial Overview
12.6. 5 SWOT Analysis
12.6. 6 Key Developments
12.7 Merck KGaA
12.7. 1 Key Facts
12.7. 2 Business Description
12.7. 3 Products and Services
12.7. 4 Financial Overview
12.7. 5 SWOT Analysis
12.7. 6 Key Developments
12.8 Novartis AG
12.8. 1 Key Facts
12.8. 2 Business Description
12.8. 3 Products and Services
12.8. 4 Financial Overview
12.8. 5 SWOT Analysis
12.8. 6 Key Developments
12.9 Astellas Pharma Inc
12.9. 1 Key Facts
12.9. 2 Business Description
12.9. 3 Products and Services
12.9. 4 Financial Overview
12.9. 5 SWOT Analysis
12.9. 6 Key Developments
12.10 Eli Lilly and Co
12.10. 1 Key Facts
12.10. 2 Business Description
12.10. 3 Products and Services
12.10. 4 Financial Overview
12.10. 5 SWOT Analysis
12.10. 6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
TABLE OF TABLES
Table 1. Oman Cancer Therapeutics Market Segmentation
Table 2. List of Vendors
Table 3. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
Table 4. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 5. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
Table 6. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
Table 7. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
Table 8. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
Table 9. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 10. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 11. List of Abbreviations
TABLE OF FIGURES
Figure 1. Impact Analysis of Drivers and Restraints
Figure 2. Oman Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
Figure 3. Heat Map Analysis by Key Players
Figure 4. Company Positioning and Concentration

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us